Prioritizing kids first is core to our mission, and our pipeline reflects that.

We believe our portfolio of technology has the potential to make a significant impact in how pediatric brain tumors are treated, as well as expand to other types of CNS tumors in adults, including glioblastoma and brain metastases.

Clinical Update BCB-276

BrainChild Bio will proceed directly to a single pivotal registrational trial, designed to accelerate the path to submit a Biologics License Application (BLA) for the treatment of children and young adults with DIPG. This clinical plan is based on alignment at a Type B meeting with the U.S. Food and Drug Administration (FDA).